JP2002517245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002517245A5 JP2002517245A5 JP2000553585A JP2000553585A JP2002517245A5 JP 2002517245 A5 JP2002517245 A5 JP 2002517245A5 JP 2000553585 A JP2000553585 A JP 2000553585A JP 2000553585 A JP2000553585 A JP 2000553585A JP 2002517245 A5 JP2002517245 A5 JP 2002517245A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- gpi
- conjugate
- antibody
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 description 45
- 102000004196 processed proteins & peptides Human genes 0.000 description 45
- 108090000765 processed proteins & peptides Proteins 0.000 description 45
- 230000001419 dependent effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000007820 coagulation assay Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8865698P | 1998-06-09 | 1998-06-09 | |
| US60/088,656 | 1998-06-09 | ||
| US10308898P | 1998-10-05 | 1998-10-05 | |
| US60/103,088 | 1998-10-05 | ||
| US09/328,199 | 1999-06-08 | ||
| US09/328,199 US6858210B1 (en) | 1998-06-09 | 1999-06-08 | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| PCT/US1999/013194 WO1999064595A1 (en) | 1998-06-09 | 1999-06-09 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002517245A JP2002517245A (ja) | 2002-06-18 |
| JP2002517245A5 true JP2002517245A5 (enExample) | 2006-08-03 |
Family
ID=27376031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553585A Pending JP2002517245A (ja) | 1998-06-09 | 1999-06-09 | 治療的および診断的ドメイン１β２ＧＰＩポリペプチドおよびその使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6858210B1 (enExample) |
| EP (1) | EP1092027B1 (enExample) |
| JP (1) | JP2002517245A (enExample) |
| KR (1) | KR20010052713A (enExample) |
| CN (1) | CN1310759A (enExample) |
| AT (1) | ATE346922T1 (enExample) |
| AU (1) | AU772851B2 (enExample) |
| CA (1) | CA2329942A1 (enExample) |
| DE (1) | DE69934228T2 (enExample) |
| ES (1) | ES2275348T3 (enExample) |
| PT (1) | PT1092027E (enExample) |
| WO (1) | WO1999064595A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5268454A (en) | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
| KR100361933B1 (ko) * | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| WO2000075105A1 (en) * | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
| CZ2002343A3 (cs) * | 1999-07-29 | 2002-08-14 | Epix Medical, Inc. | Cílená multimerní zobrazovací činidla s multilokální vazebnou schopností |
| CN1399562A (zh) * | 1999-11-28 | 2003-02-26 | 拉卓拉药物公司 | 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物 |
| AU2001268228A1 (en) * | 2000-06-08 | 2001-12-17 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| EP1360207B1 (en) * | 2000-12-13 | 2011-06-22 | Bac Ip B.V. | Protein arrays of camelid heavy-chain immunoglobulin variable domains |
| TWI221406B (en) | 2001-07-30 | 2004-10-01 | Epix Medical Inc | Systems and methods for targeted magnetic resonance imaging of the vascular system |
| US20030114405A1 (en) * | 2001-08-13 | 2003-06-19 | Linnik Matthew D. | Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function |
| JP4800614B2 (ja) | 2002-07-19 | 2011-10-26 | ザ ジェネラル ホスピタル コーポレイション | オキシム結合体、およびそれらの形成および使用のための方法 |
| AU2003303524A1 (en) * | 2002-12-27 | 2004-07-29 | La Jolla Pharmaceutical Company | Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
| DE10310082A1 (de) * | 2003-03-07 | 2004-09-16 | Ktb Tumorforschungsgesellschaft Mbh | Protein-bindende Doxorubicin-Peptid-Derivate |
| US20040258683A1 (en) * | 2003-03-30 | 2004-12-23 | Linnik Matthew D. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
| CN101146826A (zh) * | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| WO2006113720A2 (en) | 2005-04-18 | 2006-10-26 | Bio-Rad Laboratories, Inc. | Solid phase immobilization of phospholipids and cofactor proteins via covalent attachment |
| US20100021379A1 (en) * | 2006-06-29 | 2010-01-28 | The Regents Of The University Of California | Chemical Antibodies for Immunotherapy and Imaging |
| US20080015145A1 (en) | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
| EP2384440B1 (en) * | 2009-01-02 | 2015-08-12 | Flysun Development Co. Ltd | Synthetic peptides, methods and kits for diagnosing autoimmune diseases |
| WO2011163568A1 (en) | 2010-06-24 | 2011-12-29 | University Of Kansas | Conjugates comprising an n-oxime bond and associated methods |
| CN105273080A (zh) * | 2014-07-14 | 2016-01-27 | 于珮 | 一种还原型β2-糖蛋白Ⅰ的制备方法 |
| US10098960B2 (en) | 2015-04-03 | 2018-10-16 | Ucl Business Plc | Polymer conjugate |
| TWI572617B (zh) * | 2016-01-20 | 2017-03-01 | 國立陽明大學 | 重組β－醣蛋白胜肽及其於抗腫瘤之應用 |
| CN105801694A (zh) * | 2016-05-03 | 2016-07-27 | 上海科新生物技术股份有限公司 | 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体 |
| US11661447B2 (en) * | 2017-08-03 | 2023-05-30 | The Cleveland Clinic Foundation | Human β2-glycoprotein I expression |
| EP4308602A1 (en) * | 2021-03-18 | 2024-01-24 | Université de Genève | Peptides and use thereof for diagnosing and treating antiphospholipid syndrome |
| CN115894270B (zh) * | 2022-10-10 | 2024-09-06 | 深圳市迪克曼生物科技有限公司 | 一种神经酰胺及其制备方法和应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4191668A (en) | 1977-02-03 | 1980-03-04 | Scripps Clinic And Research Foundation | Induction of immunological tolerance |
| US5126131A (en) | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
| US5370871A (en) | 1983-01-24 | 1994-12-06 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
| US6022544A (en) | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
| US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
| US4751181A (en) | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
| WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| AU633488B2 (en) | 1988-04-04 | 1993-02-04 | Northwestern University | Binding of immune complexes by modified forms of c-reactive protein |
| ATE142789T1 (de) | 1989-10-19 | 1996-09-15 | Yamasa Shoyu Kk | Träger zur bindung von antiphospholipid- antikörpern, diese antikörper verwendender immunotest und kit dafür |
| US5268454A (en) | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5162515A (en) | 1990-01-16 | 1992-11-10 | La Jolla Pharmaceutical Company | Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| EP0474849B1 (en) | 1990-04-06 | 1995-09-13 | Yamasa Shoyu Co., Ltd. | Methods for determining antiphospholipid antibodies |
| WO1992011029A1 (en) | 1990-12-17 | 1992-07-09 | The Johns Hopkins University | Suppression of immune responses with oligomeric forms of antigen of controlled chemistry |
| CA2073846C (en) | 1991-07-15 | 2007-09-18 | David S. Jones | Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides |
| JP2886983B2 (ja) | 1992-02-05 | 1999-04-26 | ヤマサ醤油株式会社 | 固相試薬およびそれを用いた抗体の測定法 |
| FR2701263B1 (fr) | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps. |
| ATE359830T1 (de) | 1993-09-08 | 2007-05-15 | Jolla Pharma | Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten |
| WO1995014231A1 (en) | 1993-11-16 | 1995-05-26 | Yamasa Corporation | Method of assaying antiphospholipid antibody and kit therefor |
| FR2722991B1 (fr) | 1994-08-01 | 1996-10-11 | Orstom | Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante |
| JPH08333390A (ja) | 1995-04-07 | 1996-12-17 | Hoechst Japan Ltd | ペプチド及びそれからなる自己免疫疾患治療剤 |
| US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| US5780319A (en) | 1996-04-19 | 1998-07-14 | Pasteur Sanofi Diagnostics | Immunoassays to detect antiphospholipid antibodies |
| EP0954531A1 (en) | 1996-06-06 | 1999-11-10 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
| DE19637770A1 (de) | 1996-09-16 | 1998-03-19 | Koenig & Bauer Albert Ag | Verfahren und Anlage zum automatischen Zu- und Abführen von Rollen |
| CA2271784A1 (en) | 1996-11-12 | 1998-05-22 | City Of Hope | Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| GB9805477D0 (en) | 1998-03-13 | 1998-05-13 | Oxford Glycosciences Limited | Methods and compositions for diagnosis of rheumatoid arthritis |
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| IL125262A0 (en) | 1998-07-07 | 1999-03-12 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| IL126447A (en) | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
| US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| JP2002542819A (ja) | 1999-05-04 | 2002-12-17 | ゲネトール ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特異的免疫反応の低減方法 |
| WO2000075105A1 (en) | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
| AUPQ272699A0 (en) | 1999-09-09 | 1999-09-30 | Unisearch Limited | Use of beta2GPI in diagnostic tests for autoimmune diseases |
| CN1399562A (zh) | 1999-11-28 | 2003-02-26 | 拉卓拉药物公司 | 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物 |
| US20010051351A1 (en) | 2000-03-27 | 2001-12-13 | Racis Stanley Paul | Antigen-specific immune complex-based enzyme-linked immunosorbent assay |
| US20020150898A1 (en) | 2000-04-18 | 2002-10-17 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2001268228A1 (en) | 2000-06-08 | 2001-12-17 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| DE10048417A1 (de) | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Verbindungen mit verzweigtem Linker |
-
1999
- 1999-06-08 US US09/328,199 patent/US6858210B1/en not_active Expired - Lifetime
- 1999-06-09 AT AT99937843T patent/ATE346922T1/de active
- 1999-06-09 CA CA002329942A patent/CA2329942A1/en not_active Abandoned
- 1999-06-09 JP JP2000553585A patent/JP2002517245A/ja active Pending
- 1999-06-09 AU AU43395/99A patent/AU772851B2/en not_active Ceased
- 1999-06-09 WO PCT/US1999/013194 patent/WO1999064595A1/en not_active Ceased
- 1999-06-09 DE DE69934228T patent/DE69934228T2/de not_active Expired - Lifetime
- 1999-06-09 KR KR1020007013980A patent/KR20010052713A/ko not_active Ceased
- 1999-06-09 PT PT99937843T patent/PT1092027E/pt unknown
- 1999-06-09 ES ES99937843T patent/ES2275348T3/es not_active Expired - Lifetime
- 1999-06-09 EP EP99937843A patent/EP1092027B1/en not_active Expired - Lifetime
- 1999-06-09 CN CN99808415A patent/CN1310759A/zh active Pending
-
2004
- 2004-07-30 US US10/903,058 patent/US20050004351A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002517245A5 (enExample) | ||
| Skriner et al. | Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. | |
| Freimuth et al. | Coxsackievirus and adenovirus receptor amino-terminal immunoglobulin V-related domain binds adenovirus type 2 and fiber knob from adenovirus type 12 | |
| Czajkowsky et al. | Submolecular resolution of single macromolecules with atomic force microscopy | |
| POOLE et al. | Studies of the membrane topology of the rat erythrocyte H+/lactate cotransporter (MCT1) | |
| Lees et al. | Structure and function of proteolipids in myelin and non-myelin membranes | |
| US20060263348A1 (en) | Apolipoprotein l-i and/or derivated polypeptide for the treatment of and/or the prevention of diseases induced by trypanosoma | |
| JP2003501038A5 (enExample) | ||
| JPS6180048A (ja) | 重抗原のための螢光偏光イムノアツセイ | |
| JPH06510192A (ja) | 推定上のｈｃｖ ｅ２／ｎｓ１蛋白に対するモノクローナル抗体およびその使用方法 | |
| Berg et al. | Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited | |
| EP1985705A3 (en) | Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections | |
| Ohnuma et al. | Large hepatitis B surface antigen polypeptides of Dane particles with the receptor for polymerized human serum albumin | |
| CA1313818C (en) | Nuclear antigen la | |
| Palmer et al. | Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis | |
| Michael et al. | All eight unassigned reading frames of mouse mitochondrial DNA are expressed. | |
| JPH09509052A (ja) | 肝炎ｃ型ウイルスエンベロープ遺伝子用の哺乳動物発現系 | |
| Mygland et al. | Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis | |
| JP2008515388A5 (enExample) | ||
| JPH02479A (ja) | ｓｎＲＮＰ−Ａ抗原及びそのフラグメント | |
| Park et al. | Targeted destruction of the polymerized human serum albumin binding site within the preS2 region of the HBV surface antigen while retaining full immunogenicity for this epitope | |
| WO2003097814A3 (en) | Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins | |
| Worobec et al. | Location of the antigenic determinants of conjugative F-like pili | |
| Evans et al. | Gap junction communication channel: peptides and anti-peptide antibodies as structural probes | |
| JP2002516658A5 (enExample) |